Company intelligence / Profile preview

Immunic Therapeutics

New York City, New York, United Statesprnewswire.com ↗

Ownership: Public · IMUX
Development stage: Phase 3

Overview

Vidofludimus calcium (IMU-838) has shown therapeutic activity in phase 2 clinical trials for relapsing-remitting MS, progressive MS, and moderate-to-severe ulcerative colitis. IMU-856 demonstrated positive effects in celiac disease patients during a phase 1/1b trial, showing protection of gut architecture, symptom improvement, biomarker response, and enhanced nutrient absorption.

Therapeutic areas: GastroenterologyDermatologyOncologyNeurology
Modalities: Small molecules, orally administered
Industry: Biotech

Drug pipeline

7 assets

vidofludimus calcium

6 more assets in the full pipeline.

Request access →

Financials

Market cap: $173.5M
Total revenue: $0
Enterprise value: $19M

Beyond the preview

Go deeper on Immunic Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunic Therapeutics.

Explore the full profile